Uroacitides

尿多酸肽

Report date: 2025/07/17 17:49:35

Base Information

Drug NameUroacitides
Drug Alias Name细胞分化剂2Cell Differentiation Agent 2CDA-Ⅱ尿多酸cell differentiationa—gentll +[8] 
ClassificationNatural product/Extract > Animal extract
Mechanisms of ActionNF-kappa-B-repressing factor inhibitors
TargetsNF-kappa-B-repressing factor
Therapy Area/IndicationsMyelodysplastic SyndromesCarcinoma, Non-Small-Cell LungBreast Neoplasms
Global Approved IndicationsMyelodysplastic SyndromesCarcinoma, Non-Small-Cell LungBreast Neoplasms
Approved Indications in ChinaMyelodysplastic SyndromesCarcinoma, Non-Small-Cell LungBreast Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2004/07/23
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHefei Everlife Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTailing Biopharmaceutical Jiangsu Co Ltd
Inactive CompaniesHefei Everlife Pharmaceutical Co Ltd
Active IndicationsMyelodysplastic SyndromesCarcinoma, Non-Small-Cell LungBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeL01
Related LinksN/A